Amgen Executive Discusses Prominent Biosimilar Trends

October 21, 2021

In this interview with The Center for Biosimilars®, Amgen biosimilars expert Jen Norton discusses regulatory and policy incentives, interchangeable biosimilars, and market share gains.

Preferred Status for Semglee Will Test Value Proposition of Insulin Biosimilars
Study: Basaglar "Biosimilar" Had Strong Downward Effect on Insulin Glargine Prices
Specialty Biologics Report Predicts Rise in Biosimilar Access
Gary Lyman, MD, MPH, Explores the Progress With Oncology Biosimilars